PepGen Inc. is a biotechnology firm focused on the development of innovative therapies for treating genetic diseases
Utilizing its proprietary peptide-based technology platform, the company aims to advance the treatment options for patients suffering from a range of neuromuscular and central nervous system disorders. PepGen is dedicated to harnessing the power of targeted delivery of genetic medicines to improve patient outcomes and support the growing demand for effective gene therapies in the healthcare landscape. Through rigorous research and development, PepGen seeks to bring transformative solutions to underserved medical needs.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) for patients amenable to an exon-51 skipping approach.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular dystrophy (DMD). The FDA indicated they will provide an official clinical hold letter to the Company within 30 days.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior Vice President, Clinical Development, Steve Han, MD, PhD, MMSc.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting a short oral presentation as well as five posters at the 29th Annual Congress of the World Muscle Society (WMS), being held October 8-12, 2024 in Prague, Czech Republic.
Capricor Therapeutics Inc. (NASDAQCAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that Christopher Ashton, PhD, intends to retire from the Board of Directors effective September 30, 2024. Dr. Ashton has served on PepGen's Board of Directors since December 2019 and was a member of the audit and compensation committees.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Executive Vice President, Research & Development, Paul D. Streck, M.D., MBA.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. (“PepGen” or “the Company”) (NASDAQPEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PEPG.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2024.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. (“PepGen” or “the Company”) (NASDAQPEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PEPG.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or “the Company”) (NASDAQPEPG) for violations of the securities laws.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced positive clinical data from the first dose cohort (5 mg/kg) of PGN-EDO51, its lead investigational candidate for patients with Duchenne muscular dystrophy (DMD) whose mutations are amenable to an exon 51-skipping approach. In the ongoing CONNECT1-EDO51 Phase 2 open-label trial, PGN-EDO51 demonstrated higher levels of exon skipping than previously reported studies with other oligonucleotide therapies at similar PMO dose levels in DMD patients. The Company also reported that change from baseline in total dystrophin production and muscle-adjusted dystrophin production was comparable to, or higher than, previously reported studies with other oligonucleotide therapies at similar PMO dose levels in DMD patients. Today at 4:30 p.m. ET, the Company will host a conference call with the CONNECT1 lead investigator Dr. Hugh McMillan to discuss the data being presented.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of Afsaneh Mohebbi, Ph.D., as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA, as Senior Vice President, Investor Relations and Corporate Communications, effective immediately.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced two executive team promotions effective immediately: Michelle Mellion, M.D., to Chief Medical Officer and Hayley Parker, Ph.D., to Senior Vice President, Global Regulatory Affairs.
